<?xml version="1.0" ?>
<TimeML xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://timeml.org/timeMLdocs/TimeML_1.2.1.xsd">
<DOCID>695204078069</DOCID>
<DCT><TIMEX3 tid="t0" type="DATE" value="2017-01-29" temporalFunction="false" functionInDocument="CREATION_TIME">January 29, 2017</TIMEX3></DCT>
<TITLE>Wedbush Releases a Buy Rating on United Therapeutics</TITLE>
<TEXT>In a report issued on January 27, Liana Moussatos from Wedbush reiterated a Buy rating on United Therapeutics (NASDAQ: UTHR ), with a price target of $229 . The companys shares closed last Friday at $162.43, close to its 52-week high of $162.92. 
 
According to TipRanks.com , Moussatos is a 5-star analyst with an average return of 11.0% and a 41.9% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Lexicon Pharmaceuticals, and Pacira Pharmaceuticals. 
 
United Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $229. 
 
Based on United Therapeutics latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $408 million and quarterly net profit of $162 million. In comparison, last year the company earned revenue of $405 million and had  a net profit of $105 million. 
 
Based on the recent corporate insider activity of 96 insiders, corporate insider sentiment is negative on the stock.  Most recently, in December 2016, Richard Giltner, a Director at UTHR sold 5,000 shares for a total of $666,800. 
 
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. 
 
United Therapeutics Corp. operates as a biotechnology company. The company is engaged in development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases. United Therapeutics was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD. 
 


The post appeared first on Analyst Ratings .</TEXT>
</TimeML>
